At Moderna's analyst meeting at #ASCO24 in Chicago, Stéphane Bancel shows the Kaplan-Meier curve separation over time for the neoantigen platform in melanoma, and also discusses Moderna's intratumoral platform, and how mRNA can work with new modalities like bispecifics and cell therapies

Tim Clackson explains how IDRX-42 has been designed to eliminate resistance mutations that the current standard of care cannot handle, and discusses P1/b ORR data presented at ASCO today.

Madeleine Armstrong gives her take on data from Caribou, Summit, Daiichi Sankyo, GSK, Abbvie, and more.

From McCormick Place, Jacob Plieth previews key data from Merus, Summit, Iovance, Caribou, AstraZeneca, GSK, Gilead, and more.

Nadim Ahmed describes #ASCO24 data from today for CLN-619 and zipalertinib, and discusses taking a CD19/CD3 into the clinic for lupus.

V.P. of Clinical Operations Jack West gives his interpretation of the announcement that Summit's partner Akeso made in China that it beat Keytruda on PFS head-to-head in 1L lung. He shares his opinion of how this data could translate outside of China and what Summit's development plans are currently.

Jeb Keiper describes the HKP1 pathway and why he believes his company's expertise in precision engineering and machine learning has helped it discover and develop this asset.

Rachel Haurwitz elaborates on the data update for CB-010 that was presented at ASCO yesterday and describes why the company will push back the start of a pivotal trial approximately six months to better understand how HLA matching potentially affects efficacy.